This research evaluated the clinical stages of patients suffering from invasive breast carcinoma, and the findings revealed that there was a significant (p < 0.001) increase in the expression levels of the CTSD, EGFR, CCND1, and BCL2 genes, particularly in stage 4 in the case of the Her2, Luminal A, and Luminal B subtypes. This evidence concerns the gene BCL2 and invasive breast carcinoma.